Johnson & Johnson EBITDA 2010-2022 | JNJ

Johnson & Johnson annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Johnson & Johnson EBITDA for the quarter ending March 31, 2022 was $7.663B, a 18.49% decline year-over-year.
  • Johnson & Johnson EBITDA for the twelve months ending March 31, 2022 was $28.664B, a 14.23% increase year-over-year.
  • Johnson & Johnson 2021 annual EBITDA was $30.402B, a 26.46% increase from 2020.
  • Johnson & Johnson 2020 annual EBITDA was $24.04B, a 3.89% decline from 2019.
  • Johnson & Johnson 2019 annual EBITDA was $25.012B, a 5.77% decline from 2018.
Johnson & Johnson Annual EBITDA
(Millions of US $)
2021 $30,402
2020 $24,040
2019 $25,012
2018 $26,544
2017 $24,634
2016 $24,651
2015 $23,622
2014 $25,058
2013 $20,131
2012 $18,037
2011 $16,181
2010 $20,448
2009 $19,070
Johnson & Johnson Quarterly EBITDA
(Millions of US $)
2022-03-31 $7,663
2021-12-31 $6,752
2021-09-30 $5,696
2021-06-30 $8,553
2021-03-31 $9,401
2020-12-31 $3,687
2020-09-30 $6,275
2020-06-30 $5,730
2020-03-31 $8,348
2019-12-31 $6,200
2019-09-30 $3,511
2019-06-30 $8,917
2019-03-31 $6,384
2018-12-31 $5,303
2018-09-30 $6,572
2018-06-30 $7,069
2018-03-31 $7,600
2017-12-31 $4,788
2017-09-30 $6,804
2017-06-30 $6,230
2017-03-31 $6,812
2016-12-31 $5,663
2016-09-30 $6,478
2016-06-30 $6,082
2016-03-31 $6,428
2015-12-31 $5,004
2015-09-30 $5,206
2015-06-30 $6,785
2015-03-31 $6,627
2014-12-31 $3,850
2014-09-30 $7,897
2014-06-30 $6,720
2014-03-31 $6,591
2013-12-31 $4,004
2013-09-30 $4,766
2013-06-30 $5,918
2013-03-31 $5,443
2012-12-31 $4,261
2012-09-30 $4,750
2012-06-30 $3,044
2012-03-31 $5,982
2011-12-31 $1,379
2011-09-30 $5,045
2011-06-30 $4,346
2011-03-31 $5,411
2010-12-31 $3,159
2010-09-30 $5,065
2010-06-30 $5,075
2010-03-31 $7,149
2009-12-31 $3,453
2009-09-30 $5,090
2009-06-30 $5,077
2009-03-31 $5,450
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $465.705B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07